Menu Search

Company Announcements

Dr Martens PLC

Result of 2025 AGM

Source: RNS
RNS Number : 5713Q
Dr. Martens PLC
10 July 2025
 

10 July 2025

DR. MARTENS PLC

RESULT OF ANNUAL GENERAL MEETING

10 JULY 2025

 

The Company announces the results of voting at its Annual General Meeting held earlier today and confirms that all resolutions were duly passed on a poll with majorities as set out below.

Resolutions 1 to 18 were proposed as Ordinary Resolutions and resolutions 19 to 22 as Special Resolutions.

Resolution

 

 

 

Votes
For

(note 1)

 

%

 

 

Votes Against

(note 1)

 

%

 

 

Votes
Total

 

 

Votes Withheld

(note 2)

% Voting

Capital Instructed

01

Receive the 2025 Annual Report and Accounts

786,076,243

100.00

34,102

0.00

786,110,345

370,385

81.35%

02

Approve the Directors' Remuneration Report

782,786,026

99.59

3,213,373

0.41

785,999,399

475,436

81.34%

03

Approve the Final Dividend

786,441,111

100.00

32,729

0.00

786,473,840

6,890

81.39%

04

Elect Ije Nwokorie

711,638,324

90.49

74,812,462

9.51

786,450,786

24,049

81.38%

05

Elect Benoit Vauchy

710,606,698

90.36

75,837,289

9.64

786,443,987

30,848

81.38%

06

Elect Robert Hanson

786,302,310

99.98

134,818

0.02

786,437,128

37,707

81.38%

07

Re-elect Giles Wilson

711,569,954

90.49

74,821,751

9.51

786,391,705

83,130

81.38%

08

Re-elect Lynne Weedall

777,807,755

98.90

8,621,954

1.10

786,429,709

45,126

81.38%

09

Re-elect Robyn Perriss

782,666,553

99.52

3,762,111

0.48

786,428,664

46,171

81.38%

10

Re-elect Andrew Harrison

782,674,150

99.52

3,768,078

0.48

786,442,228

32,607

81.38%

11

Re-elect Ian Rogers

781,923,703

99.43

4,518,525

0.57

786,442,228

32,607

81.38%

12

Re-elect Paul Mason

659,171,361

88.07

89,279,024

11.93

748,450,385

38,024,450

77.45%

13

Re-elect Tara Alhadeff

700,151,020

89.26

84,277,826

10.74

784,428,846

2,045,989

81.18%

14

Re-appoint PricewaterhouseCoopers LLP as auditor

786,339,031

99.99

54,271

0.01

786,393,302

81,533

81.38%

15

Authorise the Audit & Risk Committee to determine the Auditor's remuneration

786,364,884

99.99

43,453

0.01

786,408,337

66,498

81.38%

16

Approve the removal of the 5% dilution limit for discretionary share plans

785,386,811

99.87

1,055,301

0.13

786,442,112

38,618

81.38%

17

Authorise the Company and its subsidiaries to make political donations

785,724,771

99.92

665,753

0.08

786,390,524

90,206

81.38%

18

Authorise allotment of shares

783,312,171

99.62

2,997,814

0.38

786,309,985

170,745

81.37%

19

Authorise general disapplication of pre-emption rights*

745,894,239

94.86

40,453,577

5.14

786,347,816

127,019

81.37%

20

Authorise additional disapplication of pre-emption rights*

745,011,084

94.74

41,380,015

5.26

786,391,099

83,736

81.38%

21

Authorise purchase of own shares*

771,750,586

98.19

14,255,925

1.81

786,006,511

474,219

81.34%

22

Authorise calling of general meetings on 14 days' notice*

782,554,288

99.51

3,857,228

0.49

786,411,516

63,319

81.38%

*Special Resolution

 

The votes of independent shareholders on the resolutions concerning the election or re-election of the Independent Non-Executive Directors are set out below:

Resolution

 

 

Votes
For

 

%

 

Votes Against

 

%

 

Votes
Total

 

Votes Withheld

 

% Independent

Capital Instructed

06

Elect Robert Hanson

416,359,870

99.97

134,818

0.03

416,494,688

37,707

69.83%

08

Re-elect Lynne Weedall

407,865,315

97.93

8,621,954

2.07

416,487,269

45,126

69.83%

09

Re-elect Robyn Perriss

412,724,113

99.10

3,762,111

0.90

416,486,224

46,171

69.83%

10

Re-elect Andrew Harrison

412,731,710

99.10

3,768,078

0.90

416,499,788

32,607

69.84%

11

Re-elect Ian Rogers

411,981,263

98.92

4,518,525

1.08

416,499,788

32,607

69.84%

 

Notes:

1.     Votes "For" and "Against" are expressed as a percentage of votes received.

2.     A "Vote withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.

3.     As at 6.30pm on 9 July 2025 the Company had a total of 966,341,901 ordinary shares with voting rights in issue. The total independent voting capital, used to calculate the votes of independent shareholders on resolutions 6 and 8 to 11, was 596,399,461.

4.     In accordance with Listing Rule 6.4.2(R), copies of the resolutions passed as special business will shortly be available for inspection on the National Storage Mechanism at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 

Enquiries

Company Secretariat

Paul Rolling, Head of Secretariat                                                                                                       +44 7584 243562

 

 

Investors and analysts                                                                       

Bethany Barnes, Director of Investor Relations                                                                             +44 7825 187465

                                                                                                                                                        bethany.barnes@drmartens.com

Beth Fionda, Investor Relations Manager                                                                              beth.fionda@drmartens.com

 

Press                                                                                                                                                    

Sodali & Co                                                                           

Ludo Baynham-Herd                                                                                                                          

Oliver Banks                                                                                                                                          drmartens@client.sodali.com

                                                                                                                                                                +44 207 250 1446

 

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. "Docs" or "DMs" were originally produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over 60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and wholesale channels, and in addition to its world-renowned "1460" boot its product segments span shoes including the 1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and accessories. Further information can be found at https://www.drmartensplc.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGSFLSUSEISEIW